Meeting
2019 ASCO Annual Meeting
Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Authors
Kerry Anne Rogers
The Ohio State University, Columbus, OH
Kerry Anne Rogers , Philip A. Thompson , John Nathan Allan , Morton Coleman , Jeff Porter Sharman , Bruce D. Cheson , Raquel Izumi , Melanie M. Frigault , Cheng Seok Quah , Rakesh K. Raman , Min Hui Wang , Thomas J. Kipps
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT02717611
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7530)
DOI
10.1200/JCO.2019.37.15_suppl.7530
Abstract #
7530
Poster Bd #
284
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.
First Author: Fahmin Basher
Poster
2022 ASCO Annual Meeting
Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.
First Author: L Elizabeth Budde
Poster
2022 ASCO Annual Meeting
Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.
First Author: Wojciech Jurczak
Poster
2020 ASCO Virtual Scientific Program
Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability.
First Author: John C. Byrd